Authors
Latest:
Dr. Flynn on Obinutuzumab for the Treatment of CLLJoseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Latest:
Joseph Unger on Low-Income Clinical Trial ParticipationJoseph Unger, from the SWOG Statistical Center at the Fred Hutchinson Cancer Research Center, on Low-Income Clinical Trial Participation.
Latest:
Dr Sparano on Advances in Breast Cancer Screening, Treatment, and Drug DevelopmentJoseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.
Latest:
Dr. Stilwill on Findings from the 2018 ASCO Annual Meeting in MelanomaJoseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses exciting findings in melanoma from the 2018 ASCO Annual Meeting.
Latest:
Dr. Uberti on Transplant in Myelodysplastic SyndromeJoseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).
Latest:
The Importance of Mentorship for Oncology and Hematology FellowsWhat is mentorship? The term "mentor" originates with the mythological character Mentor, with whom Odysseus entrusted his son, Telemachus. Mentor was responsible for educating and instilling values in Telemachus when Odysseus departed for the Trojan War.
Latest:
Dr. Feliciano on Nivolumab in Small Cell Lung CancerJosephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).
Latest:
Oncology Pharmacy Program Ensures Medication AdherenceThe rise of oral anticancer agents is revolutionizing cancer treatment for both patients and cancer care providers. Patients can take their medications in the comfort of their own homes without the need for needles, long stints in infusion chairs or intensive nursing oversight.
Latest:
Josh Armenia on Impact of Mutated Gene Analysis in Prostate CancerJosh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.
Latest:
Dr. Heinzerling on Stage III Treatment of NSCLCJosh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).
Latest:
Significance of Analyzing Gene Mutations in Prostate CancerJoshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.
Latest:
Dr. Bauml on the Utility of Liquid Biopsy in Metastatic NSCLCJoshua Bauml, MD, discusses the utility of liquid biopsy in metastatic non–small cell lung cancer.
Latest:
Future of R/R DLBCLA panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Latest:
Transoral Surgery for Oropharyngeal Squamous Cell CarcinomaThe incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.
Latest:
Dr Cohen on Key Trials Supporting the Use of PARP Inhibitors in Ovarian CancerJoshua G. Cohen, MD, FACOG, FACS, discusses key trials supporting the use of PARP inhibitor maintenance therapy in upfront setting in ovarian cancer.
Latest:
Clinical Decision Support Tools Deliver Benefits Beyond Improved Patient CareOne best practice identified for transforming quality, safety and efficiency in healthcare is the use of clinical decision support tools.
Latest:
Dr Meeks on Harnessing Innovation in Bladder CancerJoshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
Latest:
Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLCJoshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.
Latest:
Current and Future Use of MET Inhibitors in NSCLCHealthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
Latest:
Need for Dynamic, Predictive Biomarkers Remains PressingDespite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.
Latest:
Dr. Lawrenz on Patient Feedback of Preoperative 5-Fraction RT Sarcoma StudyJoshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.
Latest:
Dr. Meeks Discusses Smoking Status in Bladder CancerJoshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.
Latest:
Dr. Sasine on CAR T-Cell Therapy in Ovarian CancerJoshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.
Latest:
Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple MyelomaJoshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.
Latest:
Dr Richter on Ongoing Research With Bispecific Antibodies in R/R Multiple MyelomaJoshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.
